title: Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab.
authors.forename: Tawee
authors.initials: T
authors.lastname: Tanvetyanon
authors.forename: Ryan
authors.initials: R
authors.lastname: Murtagh
authors.forename: Gerold
authors.initials: G
authors.lastname: Bepler
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002543:Cerebral Hemorrhage / Q000139:chemically induced*; D017809:Fatal Outcome; D006801:Humans; D002538:Intracranial Arteriovenous Malformations / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab